# A Study of DS-3939a in Participants With Solid Tumors

> **NCT07739966** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 400 (estimated)

## Conditions studied

- Solid Tumor
- Locally Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** DS-3939a
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** DS-1103a

## Key facts

- **NCT ID:** NCT07739966
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2030-07-31
- **Final completion:** 2032-01-29
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739966, "A Study of DS-3939a in Participants With Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*